Novo Nordisk stock has delivered a decline of 35.3% over the past three years, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and the earnings multiples currently point to an undervalued profile, creating a clear tension between price performance and valuation checks.

• Over the last three years, Novo Nordisk shares are down 35.3%, which may make the current level look more like a reset than a continuation of past gains.
• Regulatory momentum around Wegovy and an ongoing share buyback program can support expectations for future cash flows, while any sustained slowdown in prescriptions for the oral Wegovy pill is a key risk for how much value the market ultimately assigns to those cash flows.
• Across Simply Wall St's broader tests, Novo Nordisk screens as undervalued in 5 of 6 checks, and the Discounted Cash Flow (DCF) estimate suggests the shares trade at a 49.2% discount to intrinsic value.

The issue now is whether that apparent discount offers a genuine margin of safety for investors, or simply reflects the risks embedded in Novo Nordisk's current obesity and hemophilia pipeline expectations.

Is Novo Nordisk a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model here estimates what Novo Nordisk’s future free cash flows could be worth in today’s terms. Based on the latest twelve-month figures, the company generated free cash flow of about DKK 48.2b, and the model assumes these cash flows continue growing rather than shrinking. This feeds into a 2 Stage Free Cash Flow to Equity framework.

On that basis, the intrinsic value for Novo Nordisk is estimated at about $97.59 per share, which sits roughly 49.2% above the current share price. On this DCF view, the stock screens as undervalued. The recent slowdown in prescriptions for the oral Wegovy pill helps explain why the market price may be lagging the value implied by those projected cash flows, even as other obesity and hemophilia assets remain in focus.

Overall, the Discounted Cash Flow (DCF) analysis suggests Novo Nordisk stock currently looks undervalued relative to the cash the business is expected to generate.

Our Discounted Cash Flow (DCF) analysis suggests Novo Nordisk is undervalued by 49.2%. Track this in your watchlist or portfolio, or discover 45 more high quality undervalued stocks.

Is Novo Nordisk a Bargain on Earnings?

The P/E ratio is a useful way to think about what you are paying today for each unit of Novo Nordisk’s earnings. Novo Nordisk currently trades on a P/E of 11.9x, which sits below both the wider pharmaceuticals industry average of 14.9x and a peer group average of 24.7x.

Simply Wall St’s model suggests a fair P/E ratio of 23.5x for Novo Nordisk, once factors such as its size, profitability profile and risk are taken into account. Against that tailored benchmark, the current 11.9x implies the stock trades on roughly half the multiple that might be expected for this type of earnings stream, even with concerns around the oral Wegovy slowdown already reflected in sentiment.

On earnings, Novo Nordisk stock appears undervalued on this basis, with its current P/E sitting well below both the fair ratio estimate and typical peer multiples.

The Novo Nordisk Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Novo Nordisk pick up where this valuation puzzle leaves off by setting out what combinations of future growth, margins and earnings would need to play out for the stock to be worth meaningfully more or less than today's price on the Community page. Each narrative links its number to a specific view of how Novo Nordisk's growth, profitability and risks might develop, giving you something concrete to revisit as fresh information comes through.

One of the top community narratives on Novo Nordisk: 48% undervalued

"Current sentiment has swung deeply negative, but expectations are now low, and the company’s pipeline is being implicitly valued at or near zero..."

Do you think there's more to the story for Novo Nordisk? Head over to our Community to see what others are saying!

The Bottom Line

Novo Nordisk screens as undervalued on both the Discounted Cash Flow (DCF) intrinsic value estimate and its current earnings multiple, which is unusual agreement across two different frameworks. That potential discount only matters if the company can convert its obesity and hemophilia pipeline into durable cash flows without a prolonged drag from the oral Wegovy slowdown. For you, the key judgment is whether current concerns around prescriptions and regulation are temporary noise or a lasting hit to what those future cash flows are worth. The answer to that question will likely determine whether the present discount is an opportunity or a value trap.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.